Airbufo Forspiro: Uses, Dosage & Side Effects
A combination inhaler containing budesonide (corticosteroid) and formoterol (long-acting bronchodilator) for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD)
Airbufo Forspiro is a combination inhaler that contains two active substances: budesonide, an inhaled corticosteroid (ICS) that reduces inflammation in the airways, and formoterol fumarate dihydrate, a long-acting beta2-adrenoceptor agonist (LABA) that relaxes the smooth muscle in the airways to improve breathing. Delivered via the Forspiro dry powder inhaler device, this medication is prescribed for the regular (maintenance) treatment of asthma in adults where both an anti-inflammatory and a long-acting bronchodilator are needed, and for the symptomatic treatment of chronic obstructive pulmonary disease (COPD) in patients who have experienced repeated exacerbations despite regular bronchodilator therapy. Airbufo Forspiro requires a prescription and must be used consistently as directed by a healthcare professional.
Quick Facts: Airbufo Forspiro
Key Takeaways
- Airbufo Forspiro combines budesonide (160 mcg, an anti-inflammatory corticosteroid) and formoterol (4.5 mcg, a fast-onset long-acting bronchodilator) in a single inhaler for convenient twice-daily maintenance therapy of asthma and COPD.
- The Forspiro device uses pre-dispensed blister strips, ensuring consistent dose delivery; it is breath-actuated, meaning it does not require coordination between pressing and breathing as with pressurized metered-dose inhalers.
- Always rinse your mouth with water after each use to reduce the risk of oral thrush (candidiasis) and hoarseness, which are the most common local side effects of the inhaled corticosteroid component.
- Airbufo Forspiro should not be used as a rescue inhaler for sudden breathing problems; patients should always carry a separate short-acting bronchodilator (e.g., salbutamol) for acute symptom relief.
- Do not stop taking Airbufo Forspiro suddenly without medical advice, even if you feel well, as abrupt discontinuation can lead to worsening symptoms and potentially dangerous asthma or COPD exacerbations.
What Is Airbufo Forspiro and What Is It Used For?
Airbufo Forspiro belongs to the therapeutic category of combination inhalers known as ICS/LABA (inhaled corticosteroid / long-acting beta2-agonist) products. This class of medication has become a cornerstone of modern respiratory medicine, recommended by the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for patients who require more than a short-acting reliever alone. The rationale for combining an anti-inflammatory agent with a bronchodilator in a single inhaler is well supported by decades of clinical research demonstrating superior outcomes compared with either component used alone.
The corticosteroid component, budesonide, is one of the most well-studied inhaled corticosteroids in clinical medicine. It works by entering the cells lining the airways and binding to glucocorticoid receptors within the cell nucleus. Once bound, budesonide suppresses the expression of multiple inflammatory genes involved in the asthmatic inflammatory cascade, including genes encoding cytokines (such as interleukin-4, interleukin-5, and interleukin-13), chemokines, adhesion molecules, and inflammatory enzymes. By reducing the underlying airway inflammation, budesonide decreases mucosal swelling, mucus hypersecretion, and bronchial hyperresponsiveness. This anti-inflammatory effect develops over days to weeks of regular use and is the foundation of asthma control.
The bronchodilator component, formoterol fumarate dihydrate, is a selective long-acting beta2-adrenoceptor agonist (LABA). Formoterol stimulates beta2-receptors on the smooth muscle cells that surround the airways, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). The rise in cAMP leads to relaxation of bronchial smooth muscle, resulting in bronchodilation. A distinctive characteristic of formoterol compared with some other LABAs is its rapid onset of action: bronchodilation begins within 1 to 3 minutes after inhalation, with peak effect occurring within approximately 2 hours. The bronchodilator effect lasts for at least 12 hours, making it suitable for twice-daily dosing. This rapid onset provides patients with prompt symptom relief while the sustained duration maintains airway patency between doses.
Airbufo Forspiro is approved by the European Medicines Agency (EMA) and regulatory authorities in multiple countries for the following therapeutic indications:
- Asthma: Regular treatment of asthma in adults (18 years and older) where the use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate. This includes patients not adequately controlled on inhaled corticosteroids alone and as-needed short-acting beta2-agonists, or patients already adequately controlled on both an inhaled corticosteroid and a long-acting beta2-agonist.
- Chronic Obstructive Pulmonary Disease (COPD): Symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) who have experienced repeated exacerbations despite regular therapy with long-acting bronchodilators. The addition of budesonide to formoterol in COPD is specifically targeted at reducing the frequency and severity of exacerbations in this high-risk population.
The combination of budesonide and formoterol has been extensively studied in large randomized controlled trials. Landmark studies such as the FACET trial, the TORCH trial (which studied a related ICS/LABA combination), and multiple Cochrane systematic reviews have consistently demonstrated that ICS/LABA combinations reduce the rate of asthma exacerbations by 25–50% compared with ICS alone, improve lung function (measured by FEV1 and peak expiratory flow), reduce symptom scores, and improve health-related quality of life. In COPD, ICS/LABA therapy has been shown to reduce exacerbation rates by approximately 25% compared with LABA alone in patients with severe disease and a history of frequent exacerbations.
The Forspiro inhaler is a dry powder inhaler (DPI) that uses pre-dispensed blister strips containing the medication. Unlike pressurized metered-dose inhalers (pMDIs), the Forspiro device is breath-actuated: you simply breathe in deeply and forcefully through the mouthpiece, and the device delivers the powder to your lungs. This eliminates the need for the press-and-breathe coordination that many patients find difficult with pMDIs. Each blister strip contains a measured dose of budesonide 160 mcg and formoterol 4.5 mcg, ensuring consistent and accurate dosing with every inhalation.
What Should You Know Before Using Airbufo Forspiro?
Contraindications
Airbufo Forspiro is contraindicated (must not be used) in patients who have a known hypersensitivity to budesonide, formoterol fumarate dihydrate, or to the excipient lactose monohydrate (which contains small amounts of milk proteins). Patients with severe milk protein allergy should not use this product. If you have experienced any allergic reaction to these substances in the past, you must inform your healthcare provider before starting treatment.
It is important to understand that Airbufo Forspiro is a maintenance medication, not a rescue treatment. It should not be used as the first-line or sole treatment for acute bronchospasm or an asthma attack. Patients must always have a separate short-acting beta2-agonist (SABA), such as salbutamol (albuterol), readily available for the relief of acute symptoms. Using a LABA without an ICS in asthma is associated with an increased risk of serious asthma-related events; however, because Airbufo Forspiro contains both an ICS and a LABA in a fixed combination, this concern does not apply to patients using it as prescribed.
Warnings and Precautions
Before starting Airbufo Forspiro, you should inform your doctor if you have or have had any of the following conditions, as they may require special monitoring or dosage adjustments:
- Active or quiescent pulmonary tuberculosis (TB) – inhaled corticosteroids may suppress local immune defenses in the lungs.
- Fungal, viral, or bacterial infections of the respiratory tract – these should be adequately treated before starting ICS therapy.
- Liver disease – budesonide is metabolized primarily by the liver (via CYP3A4), and patients with significant hepatic impairment may experience increased systemic exposure to budesonide.
- Diabetes mellitus – inhaled corticosteroids may occasionally affect blood glucose levels, particularly at higher doses or with prolonged use.
- Untreated hypokalemia – beta2-agonists may cause a decrease in serum potassium, which could be clinically significant in patients already at risk.
- Thyrotoxicosis (overactive thyroid) – the cardiovascular effects of beta2-agonists may be potentiated.
- Pheochromocytoma – a rare tumor of the adrenal gland that causes excess catecholamine production; beta2-agonists should be used with caution.
- Cardiovascular disorders – including coronary artery disease, hypertrophic obstructive cardiomyopathy, cardiac arrhythmias (especially third-degree AV block and tachyarrhythmias), severe heart failure, aortic stenosis, or prolongation of the QTc interval.
- Osteoporosis – long-term use of inhaled corticosteroids, particularly at high doses, may contribute to reduced bone mineral density.
- Adrenal insufficiency – patients transferring from systemic corticosteroids to inhaled corticosteroids may have adrenal suppression; the transition should be gradual and monitored.
Do not suddenly stop taking Airbufo Forspiro without consulting your doctor. Abrupt discontinuation of an inhaled corticosteroid can lead to rapid worsening of asthma or COPD symptoms, potentially resulting in a life-threatening exacerbation. If your symptoms are well controlled and your doctor decides to reduce your dose, this should be done gradually over several weeks.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, discuss the use of Airbufo Forspiro with your doctor before starting or continuing treatment. The decision should be based on an individual assessment of the benefits of treatment weighed against the potential risks to the developing fetus or nursing infant.
Regarding pregnancy, budesonide is one of the most extensively studied inhaled corticosteroids during pregnancy, with data from large population-based registries (including the Swedish Medical Birth Registry with over 6,000 exposed pregnancies) showing no increased risk of congenital malformations. Nevertheless, the lowest effective dose should be used, and uncontrolled asthma during pregnancy poses well-documented risks to both mother and fetus, including pre-eclampsia, preterm birth, and low birth weight. Major international guidelines, including GINA and the British Thoracic Society (BTS), recommend continuing inhaled corticosteroids during pregnancy in patients who require them for asthma control.
Regarding breastfeeding, budesonide is excreted in breast milk in small amounts. At therapeutic doses, the exposure to the infant is considered negligible. Formoterol excretion in human breast milk has not been extensively studied, but animal data suggest it is excreted in milk. The use of Airbufo Forspiro during breastfeeding should be considered only if the expected benefit to the mother outweighs any potential risk to the infant. In practice, maintenance inhaled corticosteroid therapy is generally considered compatible with breastfeeding.
How Does Airbufo Forspiro Interact with Other Drugs?
Drug interactions with Airbufo Forspiro can affect either the budesonide component or the formoterol component, or both. It is essential to inform your doctor and pharmacist about all medications you are currently taking, including prescription and over-the-counter drugs, herbal supplements, and vitamins. This section describes the most clinically important interactions. Not all possible interactions are listed; always consult your healthcare professional for a comprehensive review of your medication regimen.
Major Interactions
The following interactions are considered clinically significant and may require avoidance of the combination, dosage adjustments, or close medical monitoring:
| Interacting Drug | Mechanism | Clinical Effect | Action |
|---|---|---|---|
| Ketoconazole, Itraconazole | Potent CYP3A4 inhibition | Markedly increased systemic budesonide exposure (up to 6-fold); risk of Cushing syndrome and adrenal suppression | Avoid combination or use with extreme caution; consider alternative antifungal |
| Ritonavir, Cobicistat | Very potent CYP3A4 inhibition | Greatly increased budesonide exposure; Cushingoid features, adrenal suppression | Avoid combination; if unavoidable, monitor closely and use lowest possible dose |
| Non-selective beta-blockers (e.g., propranolol) | Beta2-receptor antagonism | Can completely abolish the bronchodilator effect of formoterol; risk of severe bronchospasm | Avoid in asthma patients; if essential, use cardioselective beta-blocker (e.g., bisoprolol) with caution |
| Quinidine, Disopyramide, Procainamide | QTc interval prolongation | Additive QTc prolongation with formoterol; increased risk of ventricular arrhythmias | Use with caution; ECG monitoring recommended |
Minor Interactions
The following interactions are of lower clinical significance but should still be considered:
| Interacting Drug | Mechanism | Clinical Effect | Action |
|---|---|---|---|
| Erythromycin, Clarithromycin | Moderate CYP3A4 inhibition | Modestly increased budesonide exposure | Usually no dose adjustment needed; monitor for corticosteroid side effects |
| Loop diuretics, Thiazides | Potassium-lowering effect | Additive hypokalemia with formoterol | Monitor serum potassium, especially during exacerbations |
| Systemic corticosteroids | Additive corticosteroid exposure | Increased risk of systemic corticosteroid side effects | Use the lowest effective dose; monitor for adrenal effects during transition |
| MAO inhibitors, Tricyclic antidepressants | Reduced metabolism of catecholamines | Potentiation of cardiovascular effects of formoterol (tachycardia, palpitations) | Use with caution; observe patient for cardiovascular symptoms |
| Phenobarbital, Phenytoin, Rifampicin | CYP3A4 induction | Reduced budesonide exposure; potentially decreased efficacy | May need higher dose of budesonide; monitor asthma/COPD control |
What Is the Correct Dosage of Airbufo Forspiro?
The dosage of Airbufo Forspiro should be individualized by a healthcare professional based on disease severity, patient response, and current level of symptom control. The general principle of inhaled corticosteroid therapy is to titrate the dose to the lowest level at which effective control is maintained. Airbufo Forspiro 160/4.5 mcg delivers a measured dose of 160 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate per inhalation to the patient.
Adults
Asthma – Maintenance Therapy
Recommended dose: 1–2 inhalations twice daily (morning and evening).
Some patients may require up to a maximum of 4 inhalations twice daily. When good asthma control is achieved and maintained, the dose should be gradually titrated down to the lowest effective dose. If your doctor prescribes 1 inhalation twice daily, and your asthma remains well controlled, you should remain on this dose. The maximum recommended daily dose for asthma is 8 inhalations (providing budesonide 1,280 mcg and formoterol 36 mcg).
COPD – Maintenance Therapy
Recommended dose: 2 inhalations twice daily.
This is the standard recommended dose for COPD. The maximum recommended daily dose in COPD is 4 inhalations (providing budesonide 640 mcg and formoterol 18 mcg). Your doctor will regularly reassess whether continued ICS/LABA therapy is appropriate for your COPD management, in line with current GOLD guidelines.
Children
Airbufo Forspiro 160/4.5 mcg is generally indicated for adults aged 18 years and older. The use of this particular strength and device in children and adolescents under 18 years has not been established in clinical trials. Lower-strength budesonide/formoterol combination products delivered via other devices may be available for pediatric use. Children with asthma should be managed by a physician experienced in pediatric respiratory medicine, and the most appropriate inhaler device and dose should be selected on an individual basis.
Elderly
There are no special dosage requirements for elderly patients. The pharmacokinetics of budesonide and formoterol in older adults are generally similar to those in younger adults. However, elderly patients may be more susceptible to certain side effects, including osteoporosis and fractures (from the corticosteroid component), cardiac effects (from the beta2-agonist component), and hypokalemia. Inhaler technique should be reviewed regularly, as age-related factors such as reduced inspiratory flow rate or cognitive decline may affect the ability to use a dry powder inhaler effectively.
Missed Dose
If you forget to take a dose of Airbufo Forspiro, take it as soon as you remember on the same day. However, if it is almost time for your next scheduled dose, skip the missed dose entirely and resume your normal dosing schedule. Do not take a double dose to compensate for a missed dose. Taking more than the prescribed amount at any one time increases the risk of side effects, including tremor, palpitations, and headache, without providing additional therapeutic benefit. If you frequently forget your doses, discuss strategies with your doctor or pharmacist, such as setting reminders or linking your inhaler use to a daily routine.
Overdose
An overdose of the formoterol component may cause tremor, headache, palpitations, tachycardia (rapid heartbeat), nausea, hyperglycemia (elevated blood sugar), and hypokalemia (low potassium levels). In severe cases, cardiac arrhythmias may occur. Treatment of formoterol overdose is supportive and symptomatic: cardioselective beta-blockers may be used with extreme caution in patients without obstructive airway disease.
Overdose of the budesonide component is unlikely to cause acute problems from a single or short-term excessive dose. Chronic excessive use of inhaled budesonide at very high doses over prolonged periods may lead to systemic corticosteroid effects such as adrenal suppression, growth retardation in children, decreased bone mineral density, cataracts, and glaucoma. If accidental overdose is suspected, seek medical attention and monitor adrenal function.
1. Open the cap of the inhaler. 2. Slide a blister strip into the device as directed. 3. Close the cap firmly until you hear a click (this pierces the blister). 4. Breathe out fully, away from the inhaler. 5. Place the mouthpiece between your lips and breathe in deeply and forcefully. 6. Hold your breath for about 10 seconds. 7. Breathe out slowly. 8. Rinse your mouth with water and spit it out after use. Always check your technique with your doctor or pharmacist regularly.
What Are the Side Effects of Airbufo Forspiro?
Like all medicines, Airbufo Forspiro can cause side effects, although not everybody gets them. Most side effects are mild to moderate in severity and are related to the known pharmacological actions of the two active components. The inhaled corticosteroid (budesonide) primarily causes local side effects in the mouth and throat, while the long-acting bronchodilator (formoterol) may cause systemic effects related to beta2-adrenergic stimulation. Understanding the frequency and nature of potential side effects helps patients recognize and manage them appropriately.
Side effects are classified according to international regulatory conventions based on their frequency of occurrence in clinical trials. If you experience any side effects that are severe, persistent, or concerning, contact your healthcare provider promptly. Seek immediate medical attention if you experience sudden worsening of breathing, chest tightness, or signs of a severe allergic reaction (such as swelling of the face, tongue, or throat, or difficulty swallowing).
Very Common
- Oral candidiasis (thrush) – a fungal infection of the mouth and throat
Common
- Headache
- Tremor (shaking, usually of the hands)
- Palpitations (awareness of heartbeat)
- Hoarseness or dysphonia (voice changes)
- Throat irritation and coughing after inhalation
- Mild bruising of the skin
Uncommon
- Tachycardia (rapid heartbeat)
- Nausea
- Muscle cramps
- Dizziness
- Sleep disturbances, including insomnia
- Restlessness, nervousness, or agitation
- Skin rash or urticaria (hives)
- Hypokalemia (low blood potassium)
Rare
- Paradoxical bronchospasm – sudden worsening of wheezing or breathing difficulty immediately after inhalation; discontinue use and seek medical attention
- Angioedema (swelling of the face, lips, tongue, or throat)
- Depression or behavioral changes
- Cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia, extrasystoles)
- Hyperglycemia (elevated blood sugar)
- Adrenal suppression – particularly with prolonged high-dose use
- Decreased bone mineral density – with long-term high-dose use
- Growth retardation in children – with prolonged high-dose use
- Glaucoma or cataracts – very rare, associated with prolonged high-dose ICS
- Anaphylactic reaction
Oral candidiasis, the most frequently reported side effect, occurs because the inhaled corticosteroid deposits in the oropharynx during inhalation, creating conditions favorable for fungal overgrowth. This can be effectively prevented or minimized by rinsing the mouth thoroughly with water after each dose and spitting the water out (do not swallow). If oral thrush develops despite preventive measures, it can typically be treated with topical antifungal agents such as nystatin or miconazole oral gel without discontinuing Airbufo Forspiro.
The tremor and palpitations associated with formoterol are dose-related and usually mild and transient, resolving after the first few days of treatment as the body adjusts to the medication. If these effects persist or are troublesome, your doctor may consider adjusting the dose.
Contact emergency services or go to the nearest emergency department immediately if you experience: sudden severe difficulty breathing or worsening of wheezing after taking a dose (paradoxical bronchospasm); swelling of the face, lips, tongue, or throat (angioedema); severe skin rash, hives, or itching; chest pain or rapid irregular heartbeat; or signs of a severe allergic reaction (anaphylaxis).
How Should You Store Airbufo Forspiro?
Proper storage of Airbufo Forspiro is essential to maintain the effectiveness and safety of the medication. The dry powder formulation is sensitive to moisture, which can cause the powder to clump and reduce the amount of medication delivered to the lungs. Follow these storage guidelines carefully:
- Temperature: Store at a temperature below 30°C (86°F). Do not freeze.
- Moisture protection: Keep the blister strips in the original sealed foil pouch until ready for use. Moisture can degrade the powder formulation and reduce dose delivery.
- After opening: Once a blister strip is removed from the foil pouch, use it within the timeframe specified in your patient information leaflet (typically within 6 months, but always check the manufacturer’s instructions).
- Keep the inhaler dry: Do not wash the Forspiro device with water. Wipe the mouthpiece with a dry cloth if needed.
- Expiry date: Do not use Airbufo Forspiro after the expiry date printed on the packaging and blister strips. The expiry date refers to the last day of that month.
- Keep out of reach of children: Store the inhaler in a safe place where children cannot access it.
Do not dispose of medicines via household waste or wastewater. Ask your pharmacist how to properly dispose of medicines you no longer use. These measures help protect the environment and ensure that unused medications do not pose a risk to others.
What Does Airbufo Forspiro Contain?
Understanding the composition of your medication is important, particularly if you have known allergies to any ingredients. Airbufo Forspiro contains the following:
Active Ingredients
- Budesonide – 160 micrograms per inhalation. Budesonide is an inhaled glucocorticosteroid with potent local anti-inflammatory activity in the airways. It has a high glucocorticoid receptor binding affinity and undergoes extensive first-pass hepatic metabolism, which limits systemic exposure and reduces the risk of systemic side effects compared with older systemic corticosteroids.
- Formoterol fumarate dihydrate – 4.5 micrograms per inhalation. Formoterol is a selective, long-acting beta2-adrenoceptor agonist that provides rapid-onset and sustained bronchodilation. It has high intrinsic activity at beta2-receptors, producing maximum relaxation of bronchial smooth muscle.
Excipient (Inactive Ingredient)
- Lactose monohydrate – used as a carrier for the dry powder inhalation formulation. Lactose helps the fine drug particles to be uniformly distributed and delivered to the lungs. Lactose monohydrate contains small amounts of milk proteins. This is important for patients with severe milk protein allergy (not the same as lactose intolerance), who should not use this product.
The pre-dispensed blister strips each contain one measured dose of the combination powder. The Forspiro inhaler device itself is a multi-dose dry powder inhaler designed to deliver the medication consistently with each actuation. There are no propellants (such as CFCs or HFAs) used in this product, unlike pressurized metered-dose inhalers, making the Forspiro a propellant-free delivery system.
Frequently Asked Questions
Both Airbufo Forspiro and Symbicort contain the same two active ingredients: budesonide and formoterol fumarate dihydrate. The primary difference lies in the inhaler device. Airbufo Forspiro is delivered via the Forspiro dry powder inhaler, which uses pre-dispensed blister strips, while Symbicort uses the Turbuhaler device. Both are equally effective when used correctly. Your doctor or respiratory nurse may recommend one device over the other based on your individual inhalation technique, inspiratory flow rate, and personal preference. If you are switching between devices, ensure you receive proper training on the new inhaler.
No, Airbufo Forspiro is a maintenance inhaler and should not be used as a rescue medication during an acute asthma attack. While formoterol has a rapid onset of action, the Forspiro device is designed for regular preventive therapy, not for emergency use. You should always carry a separate short-acting bronchodilator (such as salbutamol/albuterol) to relieve sudden symptoms. If you are using your reliever inhaler more often than usual, this may indicate worsening asthma control, and you should contact your doctor for a treatment review.
The Forspiro device uses individually sealed blister strips. Each strip contains a defined number of doses. You can track the number of doses used by counting the used blisters on each strip. The inhaler packaging and patient information leaflet specify the total number of doses per strip. When all blisters on a strip have been used, replace it with a new strip. Do not attempt to re-use a blister that has already been punctured, as it will not contain any medication.
At recommended inhaled doses, the risk to bone density is generally considered low. However, long-term use of inhaled corticosteroids, particularly at higher doses, may contribute to a modest reduction in bone mineral density. This is more relevant for patients on high-dose ICS therapy for extended periods, postmenopausal women, elderly patients, and those with additional risk factors for osteoporosis. Your doctor may recommend bone density monitoring (DEXA scan) if you are at increased risk. Adequate calcium and vitamin D intake, weight-bearing exercise, and avoiding smoking and excessive alcohol consumption are important preventive measures.
If you accidentally take more puffs than prescribed, you may experience symptoms related to formoterol overdose such as tremor, headache, rapid heartbeat, or palpitations. These effects are usually self-limiting and resolve within a few hours. A single accidental extra dose of budesonide is unlikely to cause harm. However, if you have taken significantly more than your prescribed dose, or if you feel unwell, contact your doctor, pharmacist, or poison control center for advice. Do not take additional doses to compensate; simply resume your normal schedule at the next dosing time.
Airbufo Forspiro has no known or negligible influence on the ability to drive and use machines at recommended doses. However, if you experience side effects such as dizziness, tremor, or visual disturbances, you should exercise caution when driving or operating machinery until you know how the medication affects you personally. These side effects are uncommon and typically mild and transient.
References
This article is based on the following international medical guidelines, regulatory documents, and peer-reviewed sources:
- European Medicines Agency (EMA). Airbufo Forspiro – Summary of Product Characteristics. www.ema.europa.eu.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024 Update. ginasthma.org.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2024 Report. goldcopd.org.
- Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337(20):1405-1411. doi:10.1056/NEJM199711133372001.
- Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH study). N Engl J Med. 2007;356(8):775-789. doi:10.1056/NEJMoa063070.
- Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;(5):CD005535. doi:10.1002/14651858.CD005535.pub2.
- British National Formulary (BNF). Budesonide with formoterol. National Institute for Health and Care Excellence (NICE). bnf.nice.org.uk.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. www.who.int.
- British Thoracic Society (BTS) / Scottish Intercollegiate Guidelines Network (SIGN). British Guideline on the Management of Asthma, 2024. www.brit-thoracic.org.uk.
- Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;(12):CD009019. doi:10.1002/14651858.CD009019.pub2.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in respiratory medicine, pulmonology, and clinical pharmacology.
Medical Content
iMedic Respiratory Medicine Editorial Team – specialist physicians in pulmonology with clinical experience in asthma and COPD management
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, GINA, GOLD, and BTS/SIGN guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and inhaled medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.